Department of Biochemistry, Inje University College of Medicine, Busan 47392, Korea.
Division of Biological Sciences, Sookmyung Women's University, Seoul 04310, Korea.
Int J Mol Sci. 2021 May 20;22(10):5398. doi: 10.3390/ijms22105398.
Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC inhibitors.
抑郁症是一种高发性、致残性且常常慢性化的疾病，给患者、家庭、医疗体系和经济都带来了沉重的负担。目前的治疗方法对相当一部分患者没有效果，因此我们急需开发出更广泛有效的、患者更能接受的治疗方法。人们研究了通过药物调节组蛋白乙酰化水平作为一种潜在的临床策略。组蛋白乙酰化状态被认为是抑郁症的一种潜在诊断生物标志物，而组蛋白去乙酰化酶（HDAC）抑制剂则作为一种新的治疗方法受到关注。本综述描述了目前我们对抑郁症中组蛋白乙酰化状态的认识的最新进展，以及 HDAC 抑制剂的治疗潜力。
